Health X Platform has approved a Composite Scheme of Arrangement and Amalgamation involving Microsec Resources Private Limited, Innogrow Technologies Limited, and Sastasundar Healthbuddy Limited. The restructuring aims to consolidate the healthcare services business into a single entity and create a focused financial services entity, thereby simplifying the corporate structure and enhancing shareholder value. The scheme involves the demerger of the financial services undertaking from Health X Platform Limited into Microsec Resources Private Limited, the amalgamation of Innogrow Technologies Limited with Microsec Resources Private Limited, and the amalgamation of Sastasundar Healthbuddy Limited with Health X Platform Limited.

Share Exchange Ratios

The Board has established specific share entitlement and exchange ratios for the scheme. For the demerger of the finance undertaking, Microsec Resources Private Limited will issue 1 equity share of INR 10 each for every 3 equity shares of INR 10 each held in Health X Platform Limited. Pursuant to the merger of Sastasundar Healthbuddy Limited with Health X Platform Limited, the latter will issue 85,12,168 equity shares of INR 10 each to the public shareholders of the former for 45,75,830 equity shares held. No shares will be issued for the amalgamation of Innogrow Technologies Limited as it is a wholly owned subsidiary.

Shareholding Pattern Changes

Upon effectiveness of the scheme, the shareholding pattern of Health X Platform Limited will change significantly. The public shareholding will increase from 25.93% to 41.57%, while the promoter and promoter group holding will decrease from 74.07% to 58.43%. The total number of shares will rise to 4,03,22,668. Microsec Resources Private Limited will be converted into a public company, and its shares will be listed on BSE and NSE, with public shareholding at 25.93%.

Key Financial Metrics

The demerged financial services division reported a turnover of INR 1,519.05 lakhs for the year ended March 31, 2026, representing 1.10% of the total consolidated turnover of INR 1,37,753.67 lakhs. The appointed date for the scheme is April 1, 2026, while the effective date will be determined upon the filing of the National Company Law Tribunal's sanction order with the Registrar of Companies.

Implementation Timelines

Implementation of the scheme is expected to take around 12 – 14 months subject to the receipt of the requisite approvals. Key milestones include Board Approval in June 2026, filing with Stock Exchanges and RBI, receipt of approvals in Q3 FY26-27, NCLT approval in Q4 FY26-27, and an effective date anticipated in July 2027. The scheme is subject to approvals from BSE Limited, National Stock Exchange of India, SEBI, NCLT, RBI, and respective shareholders and creditors.

Health X Platform Limited disclosed that promoter Ravi Kant Sharma sold 2,50,000 equity shares on June 3, 2026, reducing his stake in the company. The transaction, executed via a market sale, was valued at Rs. 7,49,77,528.94. This sale was conducted under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, which mandates the disclosure of changes in shareholding by promoters.

Prior to the disposal, Sharma held 9,97,393 shares, accounting for 3.14% of the company's capital. Following the sale on June 3, 2026, his holding has decreased to 7,47,393 shares, which now represents 2.35% of the share capital. The company intimated the stock exchanges regarding this transaction on June 4, 2026.

Details of Transaction

The disclosure was submitted to BSE Ltd. and the National Stock Exchange of India Ltd. The following table summarizes the change in the promoter's shareholding:

The company confirmed that there were no trades in derivatives by the promoter during this period. The filing was signed by Pratap Singh, Company Secretary & Compliance Officer of Health X Platform Limited.